surmount-1 tirzepatide non-diabetic weight loss Gastrointestinal tolerability and reduction associated with in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT‐1 to ‐4 trials - Rubino - 2025 Efficacy and Safety of Tirzepatide
Description
Your clinician will recommend the medication that makes the most sense for your health history, insurance, and goals
Six studies assessed all three eligible tirzepatide maintenance doses (5, 10 and 15 mg once-weekly), while one study included two arms with a maintenance dose of 15 mg but with two different dose-escalation regimens [18]
Have I verified whether my insurance covers brand-name GLP-1 medications (Wegovy, Zepbound)
This action is particularly beneficial for individuals with type 2 diabetes, as it helps to improve glycemic control
